v3.25.4

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 10,743	$ 11,055
Available-for-sale investments	67,944	61,070
Other receivables	873	1,736
Prepaid expenses	677	8,093
Total current assets	80,237	81,954
Restricted cash	2,235	2,951
Property and equipment, net	4,263	4,850
Operating lease, right-of-use assets	5,524	5,817
Financing lease, right-of-use assets	596	1,192
Other assets	148	66
Total assets	93,003	96,830
Current liabilities:
Accounts payable	3,891	4,323
Accrued expenses	9,791	9,392
Current portion of operating lease liability	836	711
Current portion of financing lease liability	630	541
Total current liabilities	15,148	14,967
Long-term operating lease liability, net of current portion	10,308	11,144
Long-term financing lease liability, net of current portion	259	887
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of December 31, 2025 and 2024, respectively; no shares issued or outstanding as of December 31, 2025 and 2024, respectively
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of December 31, 2025 and 2024, respectively; issued and outstanding shares - 98,031,104 as of December 31, 2025 and 84,038,922 as of December 31, 2024, respectively	98	84
Additional paid-in capital	673,554	602,021
Accumulated other comprehensive loss	(8)	(40)
Accumulated deficit	(606,164)	(532,046)
Total aTyr Pharma stockholders’ equity	67,480	70,019
Noncontrolling interest in Pangu BioPharma Limited	(192)	(187)
Total stockholders' equity	67,288	69,832
Total liabilities and stockholders’ equity	$ 93,003	$ 96,830

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

aTYR PHARMA INC 10-K